Heart rate variability and plasma lipids in men with and without ischaemic heart disease

Atherosclerosis

Volumn 145, Issue 1, 1999, Pages 181-186

  Christensen, Jeppe Hagstrup ^a   Toft, Egon ^a   Christensen, Merete Stubkjær ^b   Schmidt, Erik Berg ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Department of Medicine   (Denmark)

Author keywords

Heart rate variability; Hypercholesterolaemia; Lipids; Lipoproteins; Myocardial infarction; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MORTALITY; PRIORITY JOURNAL; SUDDEN DEATH;

ADULT; CHOLESTEROL; CORONARY DISEASE; HEART RATE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

EID: 0033009485     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00052-0     Document Type: Article

References (31)

1. Kleiger R.E., Miller J.P., Bigger J.T., Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. S9:1987;256-262.
2. Stein P.K., Bosner M.S., Kleiger R.E., Conger B.M. Heart rate variability: a measure of cardiac autonomic tone. Am Heart J. 127:1994;1376-1381.
3. Hartikainen J.K., Malik M., Staunton A., Poloniecki J., Camm J. Distinction between arrhythmic and non-arrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol. 28:1996;296-304.
4. Mølgaard H., Sørensen K.E., Bjerregaard P. Attenuated 24-h heart rate variability in apparently healthy subjects, subsequently suffering sudden cardiac death. Clin Auto Res. 1:1991;233-237.
5. Second report of the expert panel on detection, evaluation, and treatment of high cholesterol in adults (adult treatment panel II). Circulation. 89:1994;1329-1445.
6. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifugation. Clin Chem. 18:1972;499-502.
7. van Ravenswaaij-Arts C.M.A., Kollée L.A.A., Hopman J.C.W., Stoelinga G.B.A., van Geijn H.P. Heart rate variability. Ann Intern Med. 118:1993;436-447.
8. Kupari M., Virolainen J., Koskinen P., Tikkanen M.J. Short-term heart rate variability and factors modifying the risk of coronary artery disease in a population sample. Am J Cardiol. 72:1993;897-903.
9. Koskinen P., Kupari M., Virolainen J., Stjernvall J., Jolkkonen J., Tuomilehto J., Tikkanen M.J. Heart rate and blood pressure variability and baroreflex sensitivity in hypercholesterolaemia. Clin Physiol. 15:1995;483-489.
10. Bønaa K.H., Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population. The Tromsø study. Circulation. 86:1992;394-405.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
12. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 335:1996;1001-1009.
13. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
14. Downs G.R., Clearfield M., Weiss S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. Air Force/Texas Coronary Atherosclerosis Study. J Am Med Assoc. 279:1998;1615-1622.
15. van Boven Ad J. Pravastatin but not placebo reduces heart rate variability after 2 years in patients with stable angina pectoris (abstract). Circulation. 92:1995;145.
16. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation. 93:1996;1043-1065.
17. Rossonw J.E. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 76:1995;86C-92.
18. Andrews T.C., Raby K., Barry J., Naimi C.L., Allred E., Ganz P., Selwyn A.P. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
19. Chowienczyk P.J., Watts G.F., Cockcroft J.R., Ritter J.M. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 340:1992;1430-1432.
20. Eichstadt H.W., Eskotter H., Hoffmann I., Amthauer H.W., Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 76:1995;112A-125.
21. Vogel R.A., Coretti M.C., Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol. 77:1996;37-40.
22. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med. 332:1995;488-493.
23. Treasure C.B., Klein J.L., Weintraub W.S., Talley D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl J Med. 332:1995;481-487.
24. Burke A.P., Farb A., Malcom G.T., Liang Y., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. New Engl J Med. 336:1997;1276-1282.
25. Davies M.J. Pathology of arterial thrombosis. Br Med Bull. 50:1994;789-802.
26. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
27. Krakoff L.R., Dziedzic S., Mann S.J., Felton K., Yeager K. Plasma epinephrine concentration in healthy men: correlation with systolic pressure and rate-pressure product. J Am Coll Cardiol. 5:1985;352-356.
28. Kjeldsen S.E., Schork N.J., Leren P., Eide I.K. Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J. 118:1989;775-781.
29. Bravo E.L. Metabolic factors and the sympathetic nervous system. Am J Hypertens. 2:1989;339S-344.
30. George R., Ramasarma T. Nature of the stimulation of biogenesis of cholesterol in the liver by noradrenaline. Biochem J. 162:1977;493-499.
31. Maziere C., Maziere J.C., Mora L., Gardette J., Polonovski J. Epinephrine decreases low density lipoprotein processing and lipid synthesis in cultured human fibroblasts. Biochem Biophys Res Commun. 133:1985;958-963.